登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Hypofractionated Versus Conventional Chemoradiotherapy Followed by Consolidative Immunotherapy in Locally Advanced NSCLC
ClinicalTrials.gov 上登记的一项肺癌开放试验,由中山大学肿瘤防治中心牵头,本站收录的另外 1 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 2
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
- 牵头方(推断)中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面
- 研究中心重庆医科大学附属第一医院First Affiliated Hospital of Chongqing Medical University重庆医院页面
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07052669,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 6
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(6 项)收起清单
18 岁 至 75 岁;性别:不限
登记记录的入选字段
Diagnosis: Patients must have locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC), with histological or cytological confirmation of the diagnosis.
入选标准第 3 条
Women of childbearing potential (WOCBP) must agree to use contraception during the study treatment period and for 5 months after the last dose of the investigational drug (i.e., 30 days [ovulation cycle] + approximately 5 half-lives of the study drug).
入选标准第 11 条
Men who have sexual relations with WOCBP must agree to use contraception during the study treatment period and for 7 months after the last dose of the investigational drug (i.e., 90 days [sperm renewal cycle] + approximately 5 half-lives of the study drug).
入选标准第 12 条
Persistent unresolved CTCAE grade >2 toxicities from prior chemoradiotherapy.
排除标准第 22 条
Grade ≥2 pneumonitis resulting from prior chemoradiotherapy.
排除标准第 23 条
Performance Status (PS): The patient's WHO Performance Status (PS) must be 0 or 1.
入选标准第 8 条
WHO performance status score of 2-4.
排除标准第 17 条
Histological subtype of mixed small-cell and non-small-cell lung cancer. Use of immunosuppressive drugs within 28 days before treatment, except for intranasal or inhaled corticosteroids at physiological doses or systemic corticosteroids ≤10 mg/day of prednisone or equivalent.
排除标准第 3 条
History of another primary malignancy within the past 5 years, except for adequately treated basal or squamous cell carcinoma of the skin or in situ cervical cancer.
排除标准第 13 条
Pregnancy Testing: Postmenopausal women, or women who have had a negative urine or serum pregnancy test within 14 days before the study medication (HCG sensitivity ≥ 25 IU/L or equivalent).
入选标准第 9 条
Breastfeeding: Women must not be breastfeeding.
入选标准第 10 条
Males with no sperm production are exempt from contraception requirements. WOCBP who are not sexually active are exempt from contraception but must still undergo pregnancy testing as outlined above.
入选标准第 13 条
Pregnancy, breastfeeding, or not using effective contraception (for men and women of reproductive potential).
排除标准第 14 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;影像与可测量病灶。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07052669,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Signed and Dated Informed Consent: Written informed consent must be provided prior to any study procedures, with the consent form signed and dated by the participant. Age Range: Male or female patients aged 18 to 75 years. Diagnosis: Patients must have locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC), with histological or cytological confirmation of the diagnosis. Previous Treatment: Treatment-naïve or previously treated with induction chemotherapy ± immunotherapy. Tumor Sample Requirement: Tumor tissue samples must be provided, and they should be sufficient for analysis. The samples must be unstained and archived. Driver gene testing: EGFR wild-type, ALK rearrangement-negative. Life Expectancy: Patients must have an expected survival of at least 12 weeks. Performance Status (PS): The patient's WHO Performance Status (PS) must be 0 or 1. Pregnancy Testing: Postmenopausal women, or women who have had a negative urine or serum pregnancy test within 14 days before the study medication (HCG sensitivity ≥ 25 IU/L or equivalent). Breastfeeding: Women must not be breastfeeding. Women of childbearing potential (WOCBP) must agree to use contraception during the study treatment period and for 5 months after the last dose of the investigational drug (i.e., 30 days [ovulation cycle] + approximately 5 half-lives of the study drug). Men who have sexual relations with WOCBP must agree to use contraception during the study treatment period and for 7 months after the last dose of the investigational drug (i.e., 90 days [sperm renewal cycle] + approximately 5 half-lives of the study drug). Males with no sperm production are exempt from contraception requirements. WOCBP who are not sexually active are exempt from contraception but must still undergo pregnancy testing as outlined above. Organ and Bone Marrow Function: The following laboratory parameters must be met:排除标准:Exclusion Criteria:
Patients meeting any of the following criteria should not be enrolled in the study: Concurrent participation in another clinical trial, except for observational (non-interventional) studies. Histological subtype of mixed small-cell and non-small-cell lung cancer. Use of immunosuppressive drugs within 28 days before treatment, except for intranasal or inhaled corticosteroids at physiological doses or systemic corticosteroids ≤10 mg/day of prednisone or equivalent. Major surgery within 4 weeks prior to enrollment (excluding procedures for vascular access). History or active autoimmune diseases within the past two years. Active or a history of inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis). History of primary immunodeficiency. History of organ transplantation requiring immunosuppressive therapy. Average corrected QT interval (QTc) ≥470 ms calculated from three ECG cycles using the Bazett formula. Uncontrolled comorbidities, including but not limited to: Persistent or active infections. Symptomatic congestive heart failure. Poorly controlled hypertension. Unstable angina. Cardiac arrhythmias. Active peptic ulcer disease or gastritis. Active bleeding disorders. Hepatitis C or HIV infection. HBsAg-positive patients with HBV DNA >500 IU/mL. Mental or social conditions that may limit adherence to study requirements or compromise the ability to provide informed consent. Known history of tuberculosis. Receipt of a live attenuated vaccine within 30 days before study initiation or planned during the study period. History of another primary malignancy within the past 5 years, except for adequately treated basal or squamous cell carcinoma of the skin or in situ cervical cancer. Pregnancy, breastfeeding, or not using effective contraception (for men and women of reproductive potential). Presence of distant metastases. Locoregional progression making definitive concurrent chemoradiotherapy unfeasible due to normal tissue dose constraints (assessed by the radiation oncologist). WHO performance status score of 2-4. Impaired organ or bone marrow function, including: Patient withdrawal from the study. Disease progression during concurrent chemoradiotherapy. Use of immunosuppressive drugs within 28 days before the first dose of tislelizumab, except for physiological doses of intranasal or inhaled corticosteroids or systemic corticosteroids ≤10 mg/day of prednisone or equivalent. Use of corticosteroids to manage chemoradiotherapy-related toxicity is permitted. Persistent unresolved CTCAE grade >2 toxicities from prior chemoradiotherapy. Grade ≥2 pneumonitis resulting from prior chemoradiotherapy. Any prior grade ≥3 immune-related adverse event (irAE) or unresolved irAE > grade 1.
引自 ClinicalTrials.gov, NCT07052669, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07052669,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。